1
|
Wang F, Song G, Liu M, Li X and Tang H:
miRNA-1 targets fibronectin1 and suppresses the migration and
invasion of the HEp2 laryngeal squamous carcinoma cell line. FEBS
Lett. 585:3263–3269. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Liu T, Zhang M, Zhang H, Sun C and Deng Y:
Inhibitory effects of cucurbitacin B on laryngeal squamous cell
carcinoma. Eur Arch Otorhinolaryngol. 265:1225–1232. 2008.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Bezerra de Souza DL, Jerez Roig J and
Bernal MM: Laryngeal cancer survival in Zaragoza (Spain): a
population-based study. Clin Transl Oncol. 14:221–224. 2012.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Dechaphunkul T: Epidemiology, risk
factors, and overall survival rate of laryngeal cancer in
Songklanagarind Hospital. J Med Assoc Thai. 94:355–360.
2011.PubMed/NCBI
|
5
|
Pignon JP, Bourhis J, Domenge C and
Designé L: Chemotherapy added to locoregional treatment for head
and neck squamous-cell carcinoma: three meta-analyses of updated
individual data. Lancet. 355:949–955. 2000. View Article : Google Scholar : PubMed/NCBI
|
6
|
Jung KH, Kim JK, Noh JH, et al: Targeted
disruption of Nemo-like kinase inhibits tumor cell growth by
simultaneous suppression of cyclin D1 and CDK2 in human
hepatocellular carcinoma. J Cell Biochem. 110:687–696. 2010.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Meneghini MD, Ishitani T, Carter JC, et
al: MAP kinase and Wnt pathways converge to downregulate an
HMG-domain repressor in Caenorhabditis elegans. Nature.
399:793–797. 1999. View
Article : Google Scholar : PubMed/NCBI
|
8
|
Verheyen EM, Mirkovic I, MacLean SJ,
Langmann C, Andrews BC and MacKinnon C: The tissue polarity gene
nemo carries out multiple roles in patterning during Drosophila
development. Mech Dev. 101:119–132. 2001. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yasuda J, Yokoo H, Yamada T, Kitabayashi
I, Sekiya T and Ichikawa H: Nemo-like kinase suppresses a wide
range of transcription factors, including nuclear factor-κB. Cancer
Sci. 95:52–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Sampson EM, Haque ZK, Ku MC, et al:
Negative regulation of the Wnt-beta-catenin pathway by the
transcriptional repressor HBP1. EMBO J. 20:4500–4511. 2001.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Ishitani T, Ninomiya-Tsuji J and Matsumoto
K: Regulation of lymphoid enhancer factor 1/T-cell factor by
mitogen-activated protein kinase-related Nemo-like kinase-dependent
phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol.
23:1379–1389. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Castanotto D and Rossi JJ: The promises
and pitfalls of RNA-interference-based therapeutics. Nature.
457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Park F: Lentiviral vectors: are they the
future of animal trans-genesis? Physiol Genomics. 31:159–173. 2007.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Licitra L, Bernier J, Grandi C, et al:
Cancer of the larynx. Crit Rev Oncol Hematol. 47:65–80. 2003.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchese F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Cheng K and Qin B: RNA interference for
cancer therapy. Pharmaceutical Perspectives of Cancer Therapeutics.
Lu Y and Mahato RI: Springer; US: pp. 399–440. 2009, View Article : Google Scholar
|
17
|
Emami KH, Brown LG, Pitts TE, Sun X,
Vessella RL and Corey E: Nemo-like kinase induces apoptosis and
inhibits androgen receptor signaling in prostate cancer cells.
Prostate. 69:1481–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Yasuda J, Tsuchiya A, Yamada T, Sakamoto
M, Sekiya T and Hirohashi S: Nemo-like kinase induces apoptosis in
DLD-1 human colon cancer cells. Biochem Biophys Res Commun.
308:227–233. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang Y, Peng C, Wu G, et al: Expression
of NLK and its potential effect in ovarian cancer chemotherapy. Int
J Gynecol Cancer. 21:1380–1387. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tan Z, Li M, Wu W, et al: NLK is a key
regulator of proliferation and migration in gallbladder carcinoma
cells. Mol Cell Biochem. 369:27–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bai L and Zhu WG: p53: structure, function
and therapeutic applications. J Cancer Mol. 2:141–153. 2006.
|
22
|
Dey A, Verma CS and Lane DP: Updates on
p53: modulation of p53 degradation as a therapeutic approach. Br J
Cancer. 98:4–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gorospe M, Liu Y, Xu Q, Chrest FJ and
Holbrook NJ: Inhibition of G1 cyclin-dependent kinase activity
during growth arrest of human breast carcinoma cells by
prostaglandin A2. Mol Cell Biol. 16:762–770. 1996.PubMed/NCBI
|